<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="143027">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02037984</url>
  </required_header>
  <id_info>
    <org_study_id>V114-004</org_study_id>
    <nct_id>NCT02037984</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety, Tolerability and Immunogenicity of V114 in Healthy Adults and Infants (V114-004)</brief_title>
  <official_title>A Phase I-II, Randomized, Double-Blind, Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults and Infants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to assess the effect of different dose levels of pneumococcal
      polysaccharide and adjuvant on the safety and immunogenicity of V114 in healthy adults and
      infants.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will consist of 2 stages. In stage 1, adult participants will be administered a
      single dose of V114. After completion of a review of safety data from the adult cohort,
      stage 2 of the study will enroll infants. Infants will receive a 4-dose schedule of either
      an active comparator or 1 of 5 dose/adjuvant combinations of V114.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">March 2016</completion_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Geometric mean concentration (GMC) of serotype-specific pneumococcal antibody at one month following the 3rd vaccination (infant participants)</measure>
    <time_frame>One month following the 3rd vaccination (approximately 7 months of age).</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants achieving the serotype-specific threshold value of ≥ 0.35μg/mL at one month following the 3rd vaccination (infant participants)</measure>
    <time_frame>One month following the 3rd vaccination (approximately 7 months of age).</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants achieving the serotype-specific threshold value of ≥ 0.35μg/mL at one month following the 4th vaccination (infant participants)</measure>
    <time_frame>One month following the 4th vaccination (approximately 13 to 16 months of age).</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMC of serotype-specific pneumococcal antibody at one month following the 4th vaccination (infant participants)</measure>
    <time_frame>One month following the 4th vaccination (approximately 13 to 16 months of age).</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMC of serotype-specific pneumococcal antibody at one month following a single vaccination (adult participants)</measure>
    <time_frame>One month following a single vaccination.</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fold rise from baseline in GMCs of serotype-specific pneumococcal antibody at one month following a single vaccination (adult participants)</measure>
    <time_frame>Prevaccination and one month following a single vaccination.</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">340</enrollment>
  <condition>Streptococcus Pneumoniae Infection</condition>
  <condition>Pneumococcal Infections</condition>
  <arm_group>
    <arm_group_label>Adult- V114 medium dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single vaccination on day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adult-V114 maximum dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single vaccination on day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Infant-V114 medium dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A 4-dose series at 2, 4, 6, and 12 to 15 months of age.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Infant-V114 high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A 4-dose series at 2, 4, 6, and 12 to 15 months of age.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Infant-V114 maximum dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A 4-dose series at 2, 4, 6, and 12 to 15 months of age.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Infant-V114 low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A 4-dose series at 2, 4, 6, and 12 to 15 months of age.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Infant-V114 medium/high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A 4-dose series at 2, 4, 6, and 12 to 15 months of age.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Infant-Prevnar 13</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A 4-dose series at 2, 4, 6, and 12 to 15 months of age.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>V114</intervention_name>
    <description>A 0.5-mL intramuscular dose</description>
    <arm_group_label>Adult- V114 medium dose</arm_group_label>
    <arm_group_label>Adult-V114 maximum dose</arm_group_label>
    <arm_group_label>Infant-V114 medium dose</arm_group_label>
    <arm_group_label>Infant-V114 high dose</arm_group_label>
    <arm_group_label>Infant-V114 maximum dose</arm_group_label>
    <arm_group_label>Infant-V114 low dose</arm_group_label>
    <arm_group_label>Infant-V114 medium/high dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Prevnar 13</intervention_name>
    <description>A 0.5-mL intramuscular dose</description>
    <arm_group_label>Infant-Prevnar 13</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Infants -Healthy and able to attend all scheduled visits.

        Adults:

        -Highly unlikely to conceive from vaccination through to 6 weeks after administration of
        the vaccine.

        Exclusion Criteria:

        Infants and Adults

          -  Prior administration of any pneumococcal vaccine, any non-live vaccine within 14 days
             or any live vaccine within 30 days

          -  History of invasive pneumococcal disease

          -  Known hypersensitivity to any vaccine component

          -  Received systemic corticosteroids within 14 days of first vaccination

          -  Known or suspected impairment of immune function

          -  Febrile illness within 72 hours before vaccination

          -  Received blood transfusion or blood products within 30 days. Infants

          -  Mother has documented human immunodeficiency virus or is hepatitis B surface antigen
             positive

          -  Has asplenia or failure to thrive. Adults

          -  Is breastfeeding.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>2 Months</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Toll Free Number</last_name>
    <phone>1-888-577-8839</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0015)</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77555</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0006)</name>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0022)</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 20, 2014</lastchanged_date>
  <firstreceived_date>January 14, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pneumococcal Infections</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
